Results 221 to 230 of about 55,423 (289)

Safety and Efficacy Findings From a Phase Ib/II Study of ASP‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

open access: yesHead &Neck, Volume 48, Issue 1, Page 160-174, January 2026.
ABSTRACT Background ASP‐1929 photoimmunotherapy—cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation—results in rapid, selective cell killing. Methods This phase Ib/II open‐label study evaluated ASP‐1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD‐L1 ...
David M. Cognetti   +17 more
wiley   +1 more source

Anti‐PD‐1/PD‐L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges

open access: yesHealth Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Anti‐PD‐1/PD‐L1 immunotherapy has changed the treatment landscape of lung cancer. This new approach provides the ability to revitalize the immune system to specifically target and kill cancer cells, thereby creating a new treatment paradigm for patients with non‐small cell lung cancer (NSCLC).
Md Mohiuddin
wiley   +1 more source

Qualitative and Quantitative Aspects of Discrepancies between Various Methods for Microsatellite Instability Detection. [PDF]

open access: yesBalkan J Med Genet
Staninova-Stojovska M   +8 more
europepmc   +1 more source

Genetic differences between primary colorectal cancer and its paired synchronous and metachronous metastases

open access: yesInternational Journal of Cancer, Volume 158, Issue 1, Page 120-130, 1 January 2026.
What's new? Colorectal cancer (CRC) frequently metastasizes to the liver, either synchronously with primary diagnosis or metachronously, after variable time intervals. Although implicated, the role of genetic factors in driving synchronous and metachronous disease progression remains uncertain.
Marie Rajtmajerova   +16 more
wiley   +1 more source

Incidentally Detected Ductal Adenocarcinoma Presenting With Isolated Pulmonary Metastasis and a BRCA2 Mutation

open access: yesIJU Case Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background Ductal adenocarcinoma of the prostate is a rare and aggressive cancer that often presents with low prostate‐specific antigen levels and nonspecific urinary symptoms, leading to a delayed diagnosis. Mutations in DNA repair genes such as BRCA2 may render these cancers susceptible to targeted treatments. Case Presentation A 78‐year‐old
Hiroyuki Karasawa   +6 more
wiley   +1 more source

Microsatellite instability and MLH1 hypermethylation – incidence and significance in colorectal polyps in young patients

open access: green, 2007
Dean C. Koh   +5 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy